Avineuro Pharmaceuticals, Inc.
A Global Neuroscience Research And Development Company Developing novel small molecules to treat unmet medical needs in the neurological and psychiatric fields.

San Diego, CA – June 16th, 2009 – Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase I clinical studies of AVN-322, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Alzheimer’s disease. The results of Phase I studies are expected to be available in September 2009. Based on these and other results, Avineuro Pharmaceuticals, Inc. plans to advance AVN-322 into Phase II clinical trials in Q4 2009.

Contact:
Yan Lavrovsky, CEO
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive, Suite 126
San Diego, CA 92121
Tel 858-436-1537 / 858-436-1540
Fax 858-228-9798
Email: YLavrovsky@avineuro.com